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Abstract: Dental extraction has often been described as the main trigger event of osteonecrosis of the
jaws (ONJ). This longitudinal hospital-based study aimed to evaluate the outcome at 2 years of a
standardized medical-surgical protocol for dental extraction, combined with platelet rich-plasma
(PRP) application, compared with conventional protocol not combined with PRP or any other
autologous platelet concentrate in cancer (ONC) and osteometabolic (OST) patients, at risk of
bisphosphonate (BP)-related ONJ. Twenty patients were consecutively recruited: six received BPs
for cancer skeletal-related events (34.17 ± 19.97 months), while fourteen received BPs for metabolic
bone disease (74.5 ± 34.73 months). These patients underwent a standardized protocol for dental
extraction, combined with autologous PRP application in the post-extraction socket. A total of 63
dental extractions were performed (24 and 39 in ONC and OST groups, respectively). As controls,
historical cases, derived from the literature and including 171 ONC and 734 OST patients, were
considered. The outcome of the surgical treatment was successful in all patients treated with PRP:
two years after extraction, no patient had clinical or radiological signs of ONJ. When this datum
was compared with historical controls, no statistically significant differences were found (p > 0.1).
The combination of a standardized medical-surgical protocol with PRP application may contribute
to limit the occurrence of BP-related ONJ, in both ONC and OST patients. Additional prospective
studies with a larger patient sample are necessary to confirm this datum.
Keywords: platelet-rich plasma; PRP; osteonecrosis of the jaws; ONJ; bisphosphonates; dental extraction
1. Introduction
Osteonecrosis of the jaws (ONJ) is a rare but potentially severe and debilitating complication of the
jaw bones that may develop after treatments with antiresorptive or antiangiogenic drugs. It consists of
progressive bone destruction in the maxillofacial area of patients exposed to ONJ-related medication,
in the absence of a previous radiation treatment or metastasis [1,2]
Since 2003, ONJ appeared as a bisphosphonate (BP)-related class effect [3]. In the following years,
ONJ cases have been reported after treatment, including other antiresorptive drugs (AR), such as
denosumab, and antiangiogenic agents and other ‘targeted therapy’ (with and without BPs) [4–7].
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Among the AR medication, BPs are the most common agents related to ONJ. BPs are widely
prescribed to treat skeletal disorders, in order to reduce the risk of skeletal-related events, such as bone
metastasis, fractures, malignant hypercalcemia and pain in cancer patients (from now on ONC), and to
control the bone loss in patients affected by osteometabolic diseases (e.g., osteoporosis) (from now on
OST) [2,7].
Risk factors of BP-related ONJ (BRONJ) are commonly divided into three categories: systemic,
drug-related and local risk factors [2,7,8]. ONC patients have been defined at high risk of BRONJ,
even after a single dose administration of BPs, because they are contemporaneously exposed to a large
number of BRONJ risk factors. OST patients, especially those in BP-treatment for a period of time
greater than 3 years or shorter than 3 years and simultaneously affected by systemic or local risk factors,
bear a not well defined risk of developing BRONJ, but surely lower than that in ONC patients [2,9].
BPs main function is strong inhibition of the osteoclastic activity with the suppression of bone
turnover; moreover, BPs also possess anti-angiogenetic properties. The multiple and different
pharmacological actions of BPs may delay or inhibit the wound healing of tooth extraction sockets,
and they may be involved in BRONJ development [2,10–13].
Among the local risk factors, dental extraction has been described as the main trigger event in the
majority cases of reported BRONJ [2,7,12,14–16]. However, to date, the exact prevalence of BRONJ
after tooth extraction is still not well known, and several surgical protocols for dental extraction have
been proposed, with different rates of ONJ onset [2,7,9,16,17].
Recently, many authors have investigated the application of autologous platelet concentrates
(APC) in post-extraction sockets in patients at risk of BRONJ [18]. The application of APC was first
proposed by Marx et al. in 1998; from then APC have been applied in various fields of regenerative
medicine, including oral surgery [19,20].
Platelet-rich plasma (PRP), belonging to APC class, is an autologous product that consists of a high
concentration of platelets and a native concentration of fibrinogen [21,22]. Given the high concentration
of platelets, the PRP is rich in platelets granules, which contain many substances fundamental to
the promotion of the healing process (e.g., adhesive proteins, pro-coagulant factors, cytokines and
chemokines), and a great number of growth factors, such as platelet-derived growth factor (PDGF),
transforming growth factor-beta (TGF-b), epidermal growth factors (EGF) and vascular endothelial
growth factors (VEGF) [19,21,22]. Thanks to all these components, PRP promotes angiogenesis
and mucosal healing, making it an attractive product in surgical procedures on patients at risk of
BRONJ [19,21,22].
The aim of the present study was to evaluate the outcome at 2 years of a standardized
medical-surgical protocol for dental extraction, including PRP application in post-extraction sockets,
compared with conventional protocol not combined with PRP or any other APC, both in ONC and
OST patients at risk of BRONJ.
2. Materials and Methods
2.1. Study Design
A longitudinal hospital-based study on patients attending the Unit of Oral Medicine of the
University Hospital “Policlinico Paolo Giaccone” in Palermo (Italy) was performed. Patients were
consecutively enrolled from August 2015 to April 2016. A standardized medical-surgical protocol for
dental extraction [9] combined with platelet rich-plasma (PRP) application was applied to all patients
enrolled. The study protocol conformed with ethical guidelines of the 1964 Declaration of Helsinki
and its later amendments or comparable ethical standards, and it was approved by institutional review
board of the University Hospital “Policlinico Paolo Giaccone” in Palermo (approval number 6/2015)
(Table 1). Before PRP preparation and surgical procedures, all patients signed written informed consent.
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Table 1. Study steps.
Step Procedure
1th
First evaluation:
• Clinical Evaluation
• Computer Tomography (CT) prescription (when ONJ was suspected)
2nd
Second evaluation:
• Pre-operatory medical therapy prescription
• Ultrasonic periodontal debridement (when required) and oral hygiene instructions
• Platelet rich-plasma (PRP) preparation
3rd
Surgical procedures
• Dental extraction
• PRP application
• Flap suture
4th Suture removal and clinical control
5th Follow-ups at 15 days and at one-three-six-twelve-eighteen-twenty-four months
As controls, historical cases derived from the literature were considered, differentiated between
ONC (n = 171) and OST (n = 734) patients. They were discovered through published studies identified
by electronic search of PubMed, Ovide/MEDLINE, Web of Science, Embase, with prespecified English
language and human-studies restrictions. The literature search included clinical trials published up to
30 December 2018. During searching, the following search terms were used alone or in an alternate
combination: osteonecrosis, jaw, ONJ, BRONJ, dental extraction, tooth extraction. The chosen studies
reported the outcome of surgical protocols for dental extraction in ONC and OST patients at risk of
BRONJ, matching for thresholds of BP exposure time, of number of teeth extracted per patient and
follow-up term; patients did not receive any APC or adjuvant therapies. The studies chosen, published
from 2010 to 2015, included well-defined groups of patients at risk of BRONJ (at least 6 months BP by
IV exposure for ONC [23–26] and 24 months BP per os exposure for OST [23,25,27]), a well described
surgical protocol (with an average of at least 2 teeth extracted for each ONC or OST patient), and a
minimum follow up of 12 months. All the latter criteria, clustered for each risk group, matched those
of the respective study group. Studies which did not match these criteria were not considered.
2.2. Entry and Exclusion Criteria
Patients were eligible for the study if they: (I) were aged >18 years; (II) had treatment with BPs
because of the underlying disease (OST or ONC); (III) required extraction due to infective-inflammatory
dental disease; (IV) had a follow-up period of at least 24 months after dental extraction; (V) had
an absence, at baseline, of clinic-radiological signs of medication-related ONJ, according to the
Italian Societies of Maxillo-Facial Surgery and of Oral Pathology and Medicine (SICMF and SIPMO,
respectively) [28].
Patients were excluded from the study if they: (I) had clinical or radiological signs of ONJ
in the surgical area; (II) had a previous history of irradiation to the head and neck area; (III) had
neoplastic involvement of the jaws; (IV) were in poor general condition; (V) were pregnant or
breast-feeding women.
The primary endpoint was the onset of medication-related ONJ after dental extraction.
2.3. Clinical and Surgical Procedures
2.3.1. First Evaluation
During the first visit, medical, pharmacological, and dental histories of patients were recorded; in
detail. The data collected were as follows: (1) age; (2) gender; (3) reason for BPs usage; (4) BPs type;
(5) duration of BPs treatment; (6) cumulative dose of BPs; (7) history of chemotherapy; (8) concurrent
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use of other AR therapy and/or anti-angiogenic medications; (9) concurrent use of steroids; (10) other
concomitant diseases; (11) smoking habit.
In the presence of suspected ONJ, a computer tomography (CT) scan was requested.
2.3.2. Second Evaluation
All patients underwent peri-operative pharmacological treatment, based on the administration
of amoxicillin/clavulanate potassium and metronidazole. Patients with a known allergy to penicillin
received lincomycin. All patients signed a written informed consent form to acknowledge the off-label
use of metronizadole in Italy. The use of chlorhexidine 0.2% mouthwash and sodium-hyaluronate gel
(Aminogam gel, Errekappa Euroterapici S.p.A., Milan, Italy) were also prescribed (Tables 1 and 2).
Table 2. Peri-operative pharmacological treatment.
Pre-
Amoxicillin/clavulanate potassium *: 1 gr per os 3x daily starting 1 day before.
Metronidazole: 250 mg per os 2x daily starting 1 day before.
Chlorhexidine 0.2% mouthwashes 30 mL swished up to 60 s, 3x daily 7 days before.
Post-
Amoxicillin/clavulanate potassium: 1 gr per os 3x daily for 7 days.
Metronidazole: 250 mg per os 2x daily for 7 days.
Chlorhexidine 0.2% mouthwashes 30 mL swished up to 60 s, 3x daily 15 days post-operatively.
Local application of sodium-hyaluronate 3x daily 10 days post-operatively.
* Patients with a known allergy to penicillin received lincomycin (pre-operative regimens: 500 mg per os 2x daily
starting 1 day pre-operatively; post-operative regimens: 500 mg per os 2x daily for 6 days)
Autologous PRP was prepared using a commercially available system (Plateltex ACT System®,
Biomed, Modena, Italy), according to the manufacturer’s instructions. The peripheral blood was
collected in four anticoagulant citrate-dextrose, formula A (ACD-A)-containing tubes; the PRP was
prepared after centrifugation at 180 g for 10 min with a common bench centrifuge. After the platelet
count, the PRP was centrifuged at 1000 g for 10 min and platelet poor plasma (PPP) was removed, in
order to adjust the platelet concentration to 2 × 109/mL. One week before the surgical procedure, oral
hygiene instructions were reinforced in patients with poor oral hygiene.
2.3.3. Surgical Dental Extraction
For all the patients, the surgical protocol included: (1) chlorhexidine 0.2% mouthwash 30 mL swished
up to 60 s; (2) local anesthesia, achieved using 3% mepivacaine hydrochloride without adrenaline; (3)
elevation of a full-thickness mucoperiosteal flap; (4) tooth luxation and avulsion, gently performed with
elevators and forceps; (5) if necessary, subsequent osteoplasty by means of an ultrasonic surgical device
(Mectron Piezosurgery Device®, Mectron Medical Technology, Carasco, Italy); (6) debridement of the
post-extraction socket with miller surgical curette and irrigation of the sockets with rifamycin sodium;
(7) application of autologous PRP; (8) tension-free soft tissue closure (Figure 1). Before the PRP application,
gelation was induced by adding the activation solution (i.e., 1 mL of calcium gluconate enriched batroxobin
solution, from the vials provided by the manufacturer) to the PRP.
2.3.4. Follow-Up
The sutures were removed between 7–10 days after the surgical procedures. Follow-up visits were
scheduled to confirm the healing of the sockets at 1, 3, 6, 12, 18 and 24 months. Radiographic evaluations
of bone healing were scheduled at 6, 12 and 24 months. The successful treatment was defined as the
absence of clinical and radiological signs of ONJ in the surgical area after 12 months [28,29].
2.4. Statistical Analysis and Historical Controls
The statistical units are the patients who satisfy the inclusion criteria of the study. Descriptive
statistics of all data were conventionally calculated. In bivariate analysis, the χ2 test or Fisher’s exact
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test (if appropriate) was used to determine differences in the proportions of categorized variables.
Statistical analysis was performed using Stata/SE 14.1 (Stata Corporation, College Station, TX, USA)
and an alpha value of 0.05 was considered significant.Appl. Sci. 2020, 10, x FOR PEER REVIEW 6 of 12 
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3. Results
During the study period, twenty patients completed the protocol. Six patients were in treatment
with BPs for cancer skeletal-related events (ONC group), the other fourteen patients (70%) were in
treatment for metabolic bone disease (OST group) (Table 3).
Three patients (15%) received concomitant systemic corticosteroid therapy, all belonging to the
ONC group. Only four patients (20%) were no longer in treatment with BPs at the moment of the
surgical procedure, all belonging to the ONC group (7 ± 6.5 months).
In the OST group, the period of assumption of BPs was of 74.5 ± 34.73 months, most of the patients
were in treatment with alendronic acid per os (42.86%) and clodronic acid by IM (28.57%).
Sixty-three tooth extractions were made (Figure 1a): thirty-three extractions (52.38%) were from
the maxilla (eight anterior teeth, 25 posterior teeth) and thirty (47.62%) from the mandible (nine anterior
teeth, 21 posterior teeth). Twenty-four teeth were extracted in the ONC group (four teeth/patient),
while thirty-nine teeth were extracted in the OST group (2.7 teeth/patient) (Table 4).
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Table 3. Descriptive details of patients enrolled (n = 20; ONC = 6; OST = 14).
Age (yr) 72.35 (±7.19)
Gender (male/female) 4/16
ONC patients assuming zoledronic acid 6
Zoledronic acid cumulative dose (mg) 142 (±80.85)
Systemic corticosteroid therapy (yes/no) 3/6
OST patients assuming BPs 14
Alendronic acid (yes/no) 6/14
Alendronic acid cumulative dose (mg) 46,040 (±17.13)
Clodronic acid (yes/no) 4/14
Clodronic acid cumulative dose (mg) 37,800 (±9.39)
Ibandronic acid (yes/no) 2/14
Ibandronic acid cumulative dose (mg) 1 pt) 55002 pt) 18,000
Risedronic acid (yes/no) 2/14
Risedronic acid cumulative dose (mg) 1 pt) 58502 pt) 10,800
In detail, in the ONC group the duration of BPs therapy was of 34.17 ± 19.97 months; all patients
were in treatment with zoledronic acid by IV, according to the standard regimen.
Table 4. Descriptive details of the extracted teeth (total N=63).
N Extraction (%) Maxilla/Mandible Site N (%)
ONC group
24
(38.09%)
Maxilla
Anterior 3 (4.8%)
Posterior 10 (15.9)
Mandible
Anterior 2 (3.2%)
Posterior 9 (14.3%)
OST group
39
(61.9%)
Maxilla
Anterior 5 (7.9%)
Posterior 15 (23.8%)
Mandible
Anterior 7 (11.1%)
Posterior 12 (19%)
Dental extraction was indicated for thirty-five teeth due to Miller degree 3 mobility (14 and 21
in the ONC and OST groups, respectively). Eighteen teeth were extracted because of large carious
lesions that could not be treated conservatively (six and 12 in the ONC and OST groups, respectively).
The remaining ten teeth (four and six in the ONC and OST groups, respectively) were extracted for
other reasons (e.g., vertical root fracture, endodontic treatment failure).
In 24 of 63 extraction sockets (38.09%), the healing of the oral mucosa was completed at the
removal of sutures; the presence of granulation tissue was recorded in the other 39 of 63 extraction
sockets (61.9%), but, at the following visit at one month, a stable healed mucosa was recorded. In a
62-year-old woman affected by breast cancer, and in treatment with zoledronic acid for 72 months,
a small area of bone exposure was detected after fifteen days, but it was resolved completely by the
subsequent visit at one month, and never showed signs of ONJ in the follow up period.
At the 12-month follow-up visit, all patients (100%) showed no clinical or radiological sign of
BRONJ. At the most recent follow-up visit, all patients had intact mucosa and no clinical or radiological
signs of ONJ (as example see Figures 1 and 2).
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Regarding the historical controls [23–27], 16 of the 171 ONC patients developed BRONJ, while
among 734 OST patients, no case of BRONJ developed. When findings from patients treated with
PRP application were compared with those from selected historical controls, no statistically significant
differences in the BRONJ onset were found (p > 0.1, for both ONC and OST patients).
4. Discussion
ONJ is a serious adverse reaction to certain medicines usually applied in the treatment of
cancer and osteometabolic disease, related to the progressive destruction of bone in the mandible or
maxilla [2,7,9,16].
Great emphasis has been placed on preventive approaches to medication-related ONJ; however,
for teeth with a poor prognosis, dental extraction is mandatory in order to eliminate any infective
outbreaks of ONJ [9,30,31].
To date, dentoalveolar surgery is considered one of the major risk factors for developing of
ONJ, with 52 to 61% of patients affected by ONJ reporting tooth extraction as the precipitating event.
The estimated risk of ONJ in patients exposed to BPs for cancer therapy after tooth extraction ranges
from 1.6 to 14.8%, while, in osteometabolic patients, the risk of ONJ after tooth extraction is around
0.5% [7]. Recently, a growing number of authors have suggested that dental/periodontal infection
prior to dental extraction, rather tha surgical procedures, may represent the main local risk factor for
ONJ [31–34].
Even if the pathogenesis of ONJ still remains unclear, the suppression of the osteoclastic activity
and the lack of vascularization represents one of the major factors on pathogenesis of ONJ [2,7,35].
The application of APC may reduce the effects of BPs on post-extraction sockets, and it has been found
that APC improves postsurgical wound healing in dental surgeries. The application of APC is linked to
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the great number of growth factors entrapped in it, such as PDGF, TGF-b, EGF and VEGF; the release
of growth factors promotes angiogenesis and stimulates the collagen production, improving bone and
mucosal healing. In addition, APC is autologous, biocompatible and a safe product [19–22].
In the present study, the application of PRP in post-extraction sockets was found to be successful
in patients at risk due to BP assumption, as no occurrence of BRONJ was observed in a long term
follow up period. Most post-extractive sites (98.41%) revealed a complete healing of the oral mucosa at
the removal of sutures; only one site in the ONC group showed a small area of bone exposure after
fifteen days, which resolved completely before the subsequent visit, and never showed signs of ONJ
throughout the follow-up period. When findings from patients treated with PRP application were
compared with those from selected historical controls [23–27], no statistically significant differences in
the BRONJ onset were found (p > 0.1, for both ONC and OST patients). Limitations of the present
study are (1) the small sample size, especially for ONC group, due to the provisions of Decree of the
Italian Ministry of Health of 25th November 2015 (Official Gazette of the Italian Republic no. 300 of
28th December 2015) that expects use of APC only in non-cancer patients; and (2) the historical controls.
Historical cases were derived from the literature and included both ONC and OST patients who satisfy
the inclusion criteria of the study (see Section 2.3).
In ONC patients, Saia et al. evaluated the occurrence of ONJ in 60 high-risk patients exposed to
BPs, who collectively had 185 teeth extracted, and found that five patients in this group developed
ONJ. In the whole cohort, the hazard rate of ONJ was 5.6% at 1 month (n = 4) and 1.5% at 6 months
(n = 1) [23]. Ferlito et al. performed 102 tooth extractions in 43 ONC patients in treatment with
zoledronate, no ONJ were observed at 12 months [24]. Sanchis-Bielsa et al. evaluated the incidence of
ONJ after surgical extraction in 34 ONC patients treated with intravenous BPs. A total of 62 teeth were
extracted, and eight patients developed ONJ, the incidence of ONJ in terms of the number of patients
was 23.5% [26] Heufelder et al. included in a prospective study 68 patients, 50 were ONC in treatment
with BPs, the remaining 18 were OST patients as received oral BPs. In total, 205 teeth were removed
and ONJ development was observed in three ONC patients under IV BP therapy [25]. Another two
papers are worthy of note, although excluded, due to the absence of datum both on cumulative dose
and months exposition from the control ONC group chosen. Mozzati et al., in a case-control study
on tooth extractions in ONC patients on zoledronic acid therapy, performed 267 dental extractions in
85 patients, with five cases of ONJ development [36]; and Otto et al., in a retrospective cohort study,
described the outcome of 216 dental extractions on 72 patients (43 ONC patients, 29 OST patients) [15].
Seven of the 72 patients developed ONJ during the follow-up period, three patients developed ONJ
(4.2%) in four of the 216 extraction sites (1.9%). Regarding the occurrence of wound healing disturbance
and ONJ development, a malignant underlying disease and an intravenous route of BPs administration
was more common (85.7%) [15]. In OST patients, Mozzati et al. described no evidence of ONJ on
700 patients and 1480 extractions [27]. Jeong et al. investigated the incidence of ONJ patients after
surgical tooth extractions (651 teeth) in OST patients exposed to oral BPs (320 patients). Indeed, 11
patients developed ONJ with an uncommonly high incidence rate (3.44%) [37]. These cases, however,
were not included in the statistical analysis, due to the short follow-up period.
Finally, it should be noted that the present study has a long follow-up period (24 months),
that is twice as long as the period suggested to exclude the onset of ONJ, following surgical
procedures on patients at risk [28,38,39]. This characteristic of the study design counterbalances
the aforementioned limitations.
Due to their properties, APC have been successfully applied in the prevention of BRONJ by
several authors; no studies, however, evaluated the application of PRP in post-extraction dental
socket [18,36,40–45]. Scoletta et al. described the application of plasma rich in growth factors (PRGF)
in a protocol for tooth extraction in ONC patients treated with intravenous BPs in two different
studies with a follow up of at least 12 months. In the first report, sixty-four patients in treatment with
intravenous BPs (60 ONC pts, four OST patients) were enrolled; five ONC patients developed ONJ in
post-extraction sites (2.27%) [44]. In the second study sixty-three patients were enrolled (57 ONC pts,
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six OST pts), with one ONJ (0.99%) in an ONC patient [45]. Mozzati et al. described a case-control study
of tooth extraction on 176 ONC patients treated with intravenous BPs. In the study group (91 ONC
pts, 542 extractions), the application of PRGF in tooth extraction was successful, with no evidence
of ONJ with a follow up period of 24 to 60 months. Five ONJ lesions were evidenced in the control
group (85 pts, 267 extractions) [36]. In a systematic review of the literature, Del Fabbro evaluated these
three prospective studies, defining the success rate of 99.05% on a tooth basis and 97.26% on a patient
basis [18]. Recently, Asaka et al. described a case-control study, in which the application of platelet
rich-fibrin (PRF) dental extraction procedures on 102 OST patients was evaluated. No BRONJ were
observed in the study group (29 pts, 52 extractions); while, nine patients in the control group (73 pts,
166 extractions) showed a delayed recovery with bone exposure 4 weeks after surgical procedures.
The authors reported wound closure within 8 weeks and no evidence of ONJ; however, the follow up
period of the study was relatively short (i.e., 3 months) [43].
5. Conclusions
Although several protocols are available, well defined guidelines to safely manage mandatory
dental extractions are still missing. PRP is an autologous product, biocompatible, and rich in growth
factors that seem to enhance the healing of tissues in post-surgical wounds. The proposed standardized
medical-surgical protocol, based on professional oral hygiene, chlorhexidine mouthwash, perioperative
antibiotic prophylaxis, atraumatic surgery and first intention wound closure, combined with PRP
application in post-extraction socket, may contribute to limit the occurrence of BP-related ONJ, both in
ONC and OST patients. Additional prospective studies with a larger patient sample are necessary to
confirm this datum.
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